
Centene's Revenues Surge 18% to $49.6B Amid $6.7B Impairment Hit
Centene CorporationDescription
What this story covers
Centene's Q3 2025 10-Q shows 18% revenue growth to $49.6B, driven by Medicaid, Medicare, and commercial segments. HBR rose to 92.7% due to medical pressures. A $6.7B impairment led to a $6.6B net loss; adjusted EPS was $0.50. Strategic wins offset member redeterminations. Liquidity is strong.
Story snapshot
CompanyCentene Corporation
TickerCNC
VariantStandard detailed
Duration10:50
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001071739-25-000183
Full Story Script
Content not available for this story.